All Oncology News

Matthew R. Cooperberg, MD, discusses the benefits associated with active surveillance for patients with low-risk prostate cancer, as well as the development of personalized medicine.

The neutrophil-to-lymphocyte ratio is an independent factor for overall survival in patients with metastatic melanoma, whether they receive targeted therapy or immunotherapy.

In a multi-institutional collaborative study, scientists at The Wistar Institute and the Medical University of Vienna, Austria, have identified the role of tumor-infiltrating or tumor-associated B-cells (

Tisagenlecleucel (Kymriah) induced a complete remission with complete or incomplete hematologic recovery in 83% of pediatric, adolescent, and young adult patients with acute lymphoblastic lymphoma.

The effort to improve outcomes in pediatric acute lymphoblastic leukemia should follow insight provided by next-generation sequencing and appropriate use of minimal residual disease criteria.

The European Commission has approved midostaurin (Rydapt) for adults with newly diagnosed FLT3-positive acute myeloid leukemia and advanced systemic mastocytosis.

Treatment with the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel significantly improved outcomes in refractory non-Hodgkin lymphoma compared with standard therapies.

Cabozantinib and nivolumab with or without ipilimumab show activity in genitourinary tumors, particularly urothelial carcinoma, and have manageable safety profiles.

Patients with refractory chronic lymphocytic leukemia achieved a high-response rate with CD19-targeted CAR T-cell therapy JCAR014.

After a median of 10 years’ follow-up, investigators with the ICECaP Working Group have concluded that there is a strong correlation between metastasis-free survival and overall survival in patients with localized prostate cancer.

The FDA’s Oncologic Drugs Advisory Committee voted 6-6 on the potential approval of sunitinib for use as an adjuvant therapy in patients with renal cell carcinoma who have received nephrectomy and are at high risk of recurrence.

Patients who received maintenance therapy with rituximab (Rituxan) following autologous stem cell transplantation as treatment for mantle cell lymphoma had a survival advantage, according to results from a retrospective single-center study.

Barbara A. Burtness, MD, discusses the current role of immunotherapy in head and neck cancer and potential combination regimens on the horizon.

In a pooled analysis, investigators determined that ibrutinib (Imbruvica) induced an objective response rate of 66% in patients with mantle cell lymphoma.

Dmitriy Zamarin, MD, PhD, discusses immunotherapy for patients with ovarian cancer.

The combination of venetoclax and rituximab significantly improved progression-free survival compared with rituximab plus bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia (CLL),

Bhavana Pothuri, MD, discusses the available PARP inhibitors and ongoing trials further investigating these agents in ovarian cancer.

Douglas A. Levine, MD, shared his insight on how the ovarian cancer landscape has developed a more personalized treatment approach.

The FDA has approved a cabazitaxel (Jevtana) regimen of 20 mg/m2 every 3 weeks in combination with prednisone for the treatment of men with metastatic castration-resistant prostate cancer.

James L. Ferrara, MD, discusses the significance of the FDA approving tisagenlecleucel as the first CAR T-cell therapy.

Breast cancer related lymphedema, a common and painful, yet underreported side effect of surgery and radiation, is getting fresh attention, courtesy of new guidelines from internationally recognized breast surgeons.

According to a new study by UW Carbone Cancer Center researchers, a broadly applicable cancer therapy currently being developed by Cellectar Biosciences may have the potential to work in pediatric solid tumors.

Dr Olivier Elemento, a renowned computational biologist and leader in the field of computational genomics and biomedicine, has been named director of the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine.

A supplemental new drug application has been submitted for abiraterone acetate in combination with prednisone and androgen deprivation therapy for high-risk men with castration-sensitive metastatic prostate cancer.

PROSTVAC with or without GM-CSF was deemed unlikely to demonstrate an improvement in overall survival compared with placebo for patients with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer.

A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin was associated with similar graft-vs-host-disease, less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.

Adding enzalutamide to androgen deprivation therapy (ADT) significantly improved metastasis-free survival versus ADT alone in patients with nonmetastatic castration-resistant prostate cancer, according to findings from the phase III PROSPER trial.

The FDA approved the first biosimilar for the treatment of cancer. ABP-215 (bevacizumab-awwb; Mvasi), a biosimilar for bevacizumab (Avastin), is indicated for the treatment of colorectal, lung, brain, kidney, and cervical cancers in adult patients.

The FDA has granted an accelerated approval to copanlisib (Aliqopa) as a treatment for patients with relapsed follicular lymphoma who have received at least 2 least prior systemic therapies.

The FDA has accepted new drug applications supporting use of the combination of the BRAF inhibitor encorafenib and the MEK inhibitor binimetinib for BRAF-mutant advanced, unresectable or metastatic melanoma.